Kun Run Biotechnology Inc (KURU.PK)

KURU.PK on OTC Markets Group

30 Jun 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for KURU.PK


Kun Run Biotechnology, Inc. is engaged, through Hainan Zhonghe Pharmaceutical Co., Ltd. (Zhonghe), its China-based indirect subsidiary, in the development, manufacture, marketing and sale of prescription polypeptide drugs. The Company’s principal products are prescription polypeptide drugs used to treat immune system malfunction... (more)
No analyst recommendations are available for KURU.PK.


Beta: --
Market Cap(Mil.): $6.25
Shares Outstanding(Mil.): 25.00
Dividend: --
Yield (%): --


  KURU.PK Industry Sector
P/E (TTM): 1.50 35.83 39.81
EPS (TTM): 0.17 -- --
ROI: 15.08 17.03 16.23
ROE: 15.27 17.93 17.36
Search Stocks

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
Provider: GlobalData
Provider: GlobalData
Provider: MarketLine (a Datamonitor Company)

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks